Your Good Partner in Biology Research

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human glucagon-like peptide-1,GLP-1 ELISA Kit

Human glucagon-like peptide-1,GLP-1 ELISA Kit

  • 中文名稱(chēng)：
    人胰高血糖素樣肽1(GLP-1)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-E08119h
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：

    CUSABIO's GLP-1 human ELISA kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human GLP-1 in serum, plasma, or tissue homogenates. This assay uses an antibody specific to human GLP-1 coated on a 96-well plate. GLP-1 present in a sample is bound to the wells by the immobilized antibody after adding the sample into the wells. Biotinylated GLP-1 antibody is added to the wells, forming an antibody-analyte-antibody complex. HRP-conjugated avidin is pipetted to the wells and binds to the complex. A TMB substrate solution is added to the wells and color develops in proportion to the amount of GLP-1 bound. The addition of Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm using a microplate reader.

    GLP-1 is a gastrointestinal peptide that is produced by the enteroendocrine L cells and is released in response to meal intake. GLP-1 mainly functions to stimulate insulin secretion and to suppress food intake, gastric emptying, and glucagon secretion, thereby limiting postprandial glucose excursions. It is important for glucose homeostasis. It also inhibits gastrointestinal motility and secretion and thus acts as an enterogastrone and part of the "ileal brake" mechanism. GLP-1 stimulates the proliferation, differentiation, and neogenesis of β cells.

  • 別名：
    N/A
  • 縮寫(xiě)：
    GLP-1
  • 種屬：
    Homo sapiens (Human)
  • 樣本類(lèi)型：
    serum, plasma, tissue homogenates.
  • 檢測(cè)范圍：
    2.5 ng/mL-40 ng/mL
  • 靈敏度：
    0.5 ng/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Metabolism
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<15%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<15%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 線(xiàn)性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human GLP-1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)  
    1:1 Average % 96  
    Range % 87-107  
    1:2 Average % 96  
    Range % 90-106  
    1:4 Average % 95  
    Range % 86-105  
    1:8 Average % 96  
    Range % 89-100  
  • 回收率：
    The recovery of human GLP-1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 96 91-101  
    EDTA plasma (n=4) 95 89-103  
                 
                 
  • 標(biāo)準(zhǔn)曲線(xiàn)：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average    
    2.3 0.063 0.061 0.062    
    4.6 0.169 0.172 0.171    
    9.1 0.398 0.384 0.391    
    22.9 0.861 0.872 0.867    
    40 1.660 1.653 1.657    
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評(píng)價(jià)

相關(guān)產(chǎn)品

問(wèn)答及客戶(hù)評(píng)論

■ 常見(jiàn)問(wèn)題解答
Q:

關(guān)于CSB-E08119h人源胰高血糖素樣肽-1（GLP-1）ELISA試劑盒，請(qǐng)問(wèn)我們應(yīng)該如何采集血樣，是否需要在EDTA管中添加DPP-4抑制劑？ 在Cusabio的說(shuō)明中，并沒(méi)有說(shuō)明在采集血漿樣本時(shí)需要添加DPP-4抑制劑。如果我們使用Cusabio的ELISA試劑盒，是否真的不需要向樣本中添加DPP-4抑制劑呢？

A:
大多數(shù)CUSABIO ELISA試劑盒都是用于檢測(cè)天然樣本的。當(dāng)我們檢測(cè)血清或血漿樣本時(shí)，通常不會(huì)進(jìn)行特殊處理，例如向樣本中添加DPP-4抑制劑。盡管一些參考文獻(xiàn)指出DPP-4抑制劑（二肽基肽酶4抑制劑）是治療2型糖尿病的一種藥物，可以抑制胰高血糖素樣肽-1（GLP-1）和葡萄糖依賴(lài)性胰島素促泌肽（GIP）的失活，并增加內(nèi)源性GLP-1和GIP的水平。但我們從未嘗試過(guò)這種操作，不確定結(jié)果會(huì)是什么。